First Trimester In Utero Exposure to Methylphenidate

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 2, 2013, Pages 73-76

  Dideriksen, Dorthe ^a   Pottegård, Anton ^b   Hallas, Jesper ^a,b   Aagaard, Lise ^b   Damkier, Per ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; METHYLPHENIDATE; ORAL CONTRACEPTIVE AGENT; PENTAZOCINE; PHENYTOIN;

ARTICLE; ATTENTION DEFICIT DISORDER; CASE STUDY; COHORT ANALYSIS; CONGENITAL MALFORMATION; DRUG SAFETY; DRUG USE; EMBASE; FETAL ALCOHOL SYNDROME; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATION PERIOD; GROWTH RETARDATION; HUMAN; INTRAVENOUS DRUG ABUSE; LIMB MALFORMATION; MEDLINE; MENINGOMYELOCELE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW;

ADULT; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; INFANT, NEWBORN; METHYLPHENIDATE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST;

EID: 84872144201     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12034     Document Type: Article

References (21)

1. Concerta ER tablets. Physicians' Desk Reference (Electronic Version). Thomson Micromedex, Greenwood Village, CO, USA. http://www.thomsonhc.com. (last accessed on 12 September 2012).
2. Pottegård A, Bjerregaard BK, Glintborg D, Hallas J, Moreno SI. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. Eur J Clin Pharmacol 2012;68:1443-50.
3. Surely they'll outgrow ADHD! The Danish Medicines Agency June 2011. www.dkma.dk. (last accessed on 12 September 2012).
4. Cantwell DP. Hyperactive children have grown up. What have we learned about what happens to them? Arch Gen Psychiatry 1985;42:1026-8.
5. Attention deficit hyperactivity disorder. NICE clinical guideline 72, September 2008. www.nice.org.uk. (last accessed on 12 September 2012).
6. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beichman J et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry 2002;41(suppl 2):26S-48S.
7. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 9th edn. Lippincott Williams & Wilkins, Philadelphia, 2011;942-3.
8. Schardein JL. Chemically Induced Birth Defects, 3rd edn. Marcel Dekker Inc, New York, 2000;256-7.
9. In English-The Swedish Medical Birth Registry. www.socialstyrelsen.se. (last accessed on 12 September 2012).
10. Drug Analysis Prints: reported adverse reactions. www.dkma.dk. (last accessed on 12 September 2012).
11. www.prisma-statement.org. (last accessed on 12 September 2012).
12. Debooy VD, Seshia MM, Tenenbein M, Casiro OG. Intravenous pentazocine and methylphenidate abuse during pregnancy. Maternal lifestyle and infant outcome. Am J Dis Child 1993;147:1062-5.
13. Smithells RW. Thalidomide and malformations in Liverpool. Lancet 1962;1:1270-3.
14. Kopelman AE, McCullar FW, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA 1975;231:62-4.
15. Drug Analysis Prints; Drug Name: Methylphenidate. www.dkma.dk. (last accessed on 12 September 2012).
16. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, MA, 1977;346-7.
17. Wajnberg R, Diav-Citrin O, Shechtman S, Ornoy A. Pregnancy outcome after in-utero exposure to methylphenidate: a prospective comparative cohort study. Reprod Toxicol 2011;13:255-68.
18. Metylfenidat. Läkemedel och fosterpåverkan. http://www.janusinfo.se. (last accessed on 12 September 2012).
19. Schardein JL. Chemically induced birth defects. 3rd ed. New York: Marcell Dekker Inc., 2000;12-7.
20. Oakley GP. Frequency of human congenital malformations. Clin Perinatol 1986;13:545-54.
21. Guideline on risk assessment of medical products on human reproduction and lactation: from data to labeling. EMEA/CHMP/203927/2005. www.ema.europa.eu. (last accessed on 12 September 2012).